Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: Role of Ack1 in polyubiquitination of tumor suppressor Wwox

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10514-10523

  Mahajan, Nupam P ^a   Whang, Young E ^a   Mohler, James L ^a,b   Earp, H Shelton ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACK1 INTERACTING PROTEIN; ANDROGEN; CHAPERONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK PROTEIN 90BETA; MUTANT PROTEIN; OXIDOREDUCTASE; PROTEIN; PROTEIN ACK1; PROTEIN TYROSINE KINASE; PROTEIN WWOX; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL STRAIN LNCAP; DISSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE CONTROL; GENETIC VARIABILITY; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA SPLICING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; UBIQUITINATION;

AMINO ACID SEQUENCE; ANIMALS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TYROSINE; UBIQUITIN;

EID: 28544438918     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1127     Document Type: Article

References (54)

1. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002;2:351-60.
2. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949.
3. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.
4. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5.
5. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.
6. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
7. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
8. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
9. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
10. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6:517-27.
11. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60:6841-5.
12. Liu Y, Majumder S, McCall W, et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005;65:3404-9.
13. Wu YM, Robinson DR, Rung HJ. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res 2004;64:7311-20.
14. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 1994;6:647-57.
15. Mahajan NP, Earp SH. An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1, and the Mer receptor tyrosine kinase. J Biol Chem 2003;278:42596-603.
16. Scott RS, McMahon EJ, Pop SM, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001;411:207-11.
17. Varnum BC, Young C, Elliott G, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995;373:623-6.
18. Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H, Hammonds RG. Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell 1995;82:355-8.
19. Manser E, Leung T, Salihuddin H, Tan L, Lim L. A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 1993;363:364-7.
20. Eisenmann KM, McCarthy JB, Simpson MA, et al. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1999;1:507-13.
21. Teo M, Tan L, Lim L, Manser E. The tyrosine kinase ACK1 associates with clathrin-coated vesicles through a binding motif shared by arrestin and other adaptors. J Biol Chem 2001;276:18392-8.
22. Worby CA, Simonson-Leff N, Clemens JC, et al. Drosophila Ack targets its substrate, the sorting nexin DSH3PX1, to a protein complex involved in axonal guidance. J Biol Chem 2002;277:9422-8.
23. Sem KP, Zahedi B, Tan I, Deak M, Lim L, Harden N. ACK family tyrosine kinase activity is a component of Dcdc42 signaling during dorsal closure in Drosophila melanogaster. Mol Cell Biol 2002;22:3685-97.
24. Hoffman GR, Cerione RA. Flipping the switch: the structural basis for signaling through the CRIB motif. Cell 2000;102:403-6.
25. Yokoyama N, Miller TW. Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. J Biol Chem 2003;278:47713-23.
26. Mott HR, Owen D, Nietlispach D, et al. Structure of the small G protein Cdc42 bound to the GTPase-binding domain of ACK. Nature 1999;399:384-8.
27. Morreale A, Venkatesan M, Mott HR, et al. Structure of Cdc42 bound to the GTPase binding domain of PAK. Nat Struct Biol 2000;7:384-8.
28. Kato J, Kaziro Y, Satoh T. Activation of the guanine nucleotide exchange factor Db1 following ACK1-dependent tyrosine phosphorylation. Biochem Biophys Res Commun 2000;268:141-7.
29. Caplan AJ, Jackson S, Smith D. Hsp90 reaches new heights. Conference on the Hsp90 chaperone machine. EMBO Rep 2003;4:126-30.
30. Panaretou B, Prodromou C, Roe SM, et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 1998;17:4829-36.
31. An WG, Schnur RC, Neckers L, Blagosklonny MV. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 1997;40:60-4.
32. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-801.
33. Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001;61:8068-73.
34. Paige AJ, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A 2001;98:11417-22.
35. Chang NS, Pratt N, Heath J, et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 2001;276:3361-70.
36. Carter BS, Ewing CM, Ward WS, et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A 1990;87:8751-5.
37. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 1996;56:5605-9.
38. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-5.
39. Aqeilan RI, Pekarsky Y, Herrero JJ, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A 2004;101:4401-6.
40. Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004;100:1605-14.
41. Nunez MI, Ludes-Meyers J, Abba MC, et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 2005;89:99-105.
42. Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 2004;10:3053-8.
43. Chang NS, Doherty J, Ensign A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem 2003;278:9195-202.
44. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
45. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
46. Neckers L. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 2002;8:962-6.
47. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003;30:709-16.
48. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-43.
49. Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma Cancer Res 2002;62:2258-60.
50. Watson JE, Doggett NA, Albertson DG, et al. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 2004;23:3487-94.
51. Sudol M, Hunter T. NeW wrinkles for an old domain. Cell 2000;103:1001-4.
52. Ilsley JL, Sudol M, Winder SJ. The WW domain: linking cell signalling to the membrane cytoskeleton. Cell Signal 2002;14:183-9.
53. Watanabe A, Hippo Y, Taniguchi H, et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 2003;63:8629-33.
54. Nur-E-Kamal A, Zhang A, Keenan SM, et al. Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells. Mol Cancer Res 2005;3:297-305.